About

Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.

Articles

Rotational Atherectomy: A Contemporary Appraisal

Citation:

Interventional Cardiology Review 2019;14(3):182–9.

New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease

Published:

26 February 2020

Citation:

European Cardiology Review 2020;15:e04.

Role of PGC-1-alpha-associated Mitochondrial Biogenesis in Statin-induced Myotoxicity

Citation:

European Cardiology Review 2020;15:e35.

Statins and Insulin Resistance

Citation:

European Cardiology Review 2020;15:e44.